Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Market Closed - Nasdaq
Other stock markets
 02:00:00 04/05/2024 am IST 		5-day change 1st Jan Change
13.16 USD -2.95% Intraday chart for Entrada Therapeutics, Inc. +5.70% -12.79%
13/03 Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
13/03 Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Entrada Therapeutics Adds President Role to COO Nathan Dowden
Sector Update: Health Care Stocks Gain Pre-Bell Wednesday
Entrada Therapeutics Promotes Nathan J. Dowden to President
Entrada Therapeutics, Inc. Announces Board Changes
US Equity Markets Close Higher Wednesday Following Consumer Sentiment Data
Sector Update: Health Care Stocks Advance Late Afternoon
Top Midday Decliners
Sector Update: Health Care Stocks Higher in Afternoon Trading
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
Entrada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Entrada Therapeutics, Inc. Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
Entrada Therapeutics, Inc. Appoints Gina Chapman to its Board of Directors, Effective September 1, 2023
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Entrada Therapeutics Gets UK Nod To Initiate Duchenne Muscular Dystrophy Trial
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of Entr-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
Insider Sell: Entrada Therapeutics
Insider Sell: Entrada Therapeutics
Insider Sell: Entrada Therapeutics
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. News Entrada Therapeutics, Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW